Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

COVID-19 and Commercial Contracts: Is it Time to Modify?

Client Alert

The coronavirus (“COVID-19”) pandemic will likely create hardship for parties attempting to perform under many types of commercial contracts. Significantly, contracts requiring travel and/or involving the provision of goods and services are likely to be substantially impaired or impacted.

What to Do Now?

Inflexibility and hard line approaches may lead to disputes and expensive litigation. Global pandemic on the scale of COVID-19 has not occurred in over a century. For the modern business world and the United States legal system, this is truly a case of first impression. In order to avoid uncertainty, communication with counterparts regarding modification of existing obligations, may be prudent and lead to reasonable, mutually acceptable adjustments to the parties original deal. 

Nevertheless, you should carefully review the material terms and conditions of your existing agreements to ensure you are informed as to your rights, obligations and likelihood of breach or timely performance.

Communicate and Modify

Now may be the best time to modify existing agreements. Following an honest assessment of each unique situation, parties are encouraged to cooperatively determine a path forward. Communicate with your counterparts and willingly work towards a mutually beneficial arrangement. Reasonable business partners will understand that the current pandemic was likely not within the contemplation of the parties when they entered into their agreement. Any such modification must be reduced to writing, signed by both parties and incorporated into the original contract.  

Common terms to modify:

  • Contract duration
  • The goods/services involved in the contract
    • Adding or subtracting goods/services covered in the contract
  • The payment terms
  • The delivery terms

Before negotiating modification, consider the following:

  • Identify changes you feel are necessary and appropriate
  • Note any contract provisions that seem unfair or unnecessary
  • Note the date, time, and location when you chose to make modifications to the contract
  • Determine the justification for modification (i.e. workforce, government directives, supplies, shipping restraints, etc… simply citing COVID-19 likely not enough)
  • Try to predict how the changes might affect all parties' contract rights

In the event a party to a contract alleges it cannot perform as a result of COVID-19, the contract may provide guidance concerning legal rights and obligations. Most commercial contracts address the parties’ rights in the event of situations occurring outside of the control of either party. Most commonly, parties may be forced to interpret and/or rely on a ‘force majeure’ clause. Generally, a ‘force majeure’ clause relieves one party from performing a contractual obligation under certain circumstances that would make performance impractical, impossible, or even illegal. Pandemic may be a defined term, but more likely, the ‘force majeure’ language will not be so specific.  However, parties should be careful of claiming a force majeure event prior to experiencing an actual delay or other impact.

The Contract Matters

The extent to which COVID-19 excuses or extends contractual obligation(s) is a fact-specific determination that will depend on the nature of the obligations and the specific language of the contract. More specifically, in the context of COVID-19, parties will want to take the following steps:

  • Read the contract;
    • Determine the extent to which the contract provides for suspension or termination of performance;
    • Identify key provisions of contracts that may be affected by COVID-19 (e.g., representations/warranties, covenants, delay rights, termination rights, conditions, ‘force majeure’ clauses);
    • Identify notice requirements that have been or may be triggered;
  • Determine the extent to which COVID-19 prevented the party asserting an inability to perform;
    • Consider whether there are alternative means to perform contractual obligations or proactive steps that can be taken anticipating the potential future effects;
  • Determine whether the party asserting COVID-19 as a justification not to perform had the ability to mitigate its effect and the ability to perform.
  • Analyze the potential consequences of a material breach and/or default;
  • Manage communications with your counterparts, while coordinating internally to ensure a consistent approach; and
  • Regularly review and update relevant regulations (e.g., local, state, national directives on health and safety) in real time to determine whether they require steps or decisions that may affect contractual commitments.

In these uncertain times, Brennan Manna Diamond is here to provide clarity and comfort. Feel free to reach out to a BMD professional for guidance as you work through your analysis.


Ohio Board of Pharmacy Update: Key Regulatory Changes and Proposals You Need to Know

The Ohio Board of Pharmacy (BOP) has rescinded certain OAC rules (OAC 4729:5-18-01 through 4729:5-18-06), removing regulations on office-based opioid treatment (OBOT) clinics. The rescissions took effect on June 3, 2024. The BOP also published a new rule, OAC 4729:8-5-01, which sets explicit reporting guidelines for licensed dispensaries and became effective on June 7, 2024.

LGBTQIA+ Patients and Discrimination in Healthcare

In early April, the Kaiser Family Foundation released a study outlining the challenges that LGBT adults face in the United States related to healthcare. According to the study, LGBT patients are “twice as likely as non-LGBT adults to report negative experiences while receiving health care in the last three years, including being treated unfairly or with disrespect (33% v. 15%) or having at least one of several other negative experiences with a provider (61% v. 31%), including a provider assuming something about them without asking, suggesting they were personally to blame for a health problem, ignoring a direct request or question, or refusing to prescribe needed pain medication.”

Ohio Recovery Housing Overhaul: New Standards and Certification Requirements Reshape Sober Living Spaces

Ensuring Fair Access: SB 269 Protects Affordable Medication for Low-Income Patients

SB 269, introduced on December 19, 2023, will ensure that 340B covered entities, including Federally Qualified Health Centers, Ryan White Clinics, disproportionate share hospitals, and Title X clinics, can acquire 340B drugs without facing undue restrictions or discriminatory practices from drug manufacturers and distributors. This protection is crucial for 340B covered entities to continue to provide affordable medications and comprehensive services to low-income patients.

Unveiling Ohio's Pharmacy Board Updates for Distributors, Mobile Clinics, and Controlled Substances

The Ohio Board of Pharmacy will hold a public hearing on May 28, 2024, to discuss several proposed changes and additions to Ohio Administrative Code (OAC). These changes pertain to terminal distributors of dangerous drugs (TDDDs), mobile clinics or medication units, and the classification of controlled substances.